已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

医学 舞蹈病 安慰剂 临床全球印象 回廊的 亨廷顿病 随机对照试验 疾病 内科学 物理疗法 儿科 替代医学 病理
作者
Samuel Frank,Claudia Testa,David Stamler,Elise Kayson,Charles S. Davis,Mary Edmondson,Shari Kinel,Blair R. Leavitt,David Oakes,Christine O’Neill,Christina Vaughan,Jody Goldstein,Margaret Herzog,Victoria Snively,Jacquelyn Whaley,Cynthia Wong,Greg Suter,Joseph Jankovic,Joohi Jimenez-Shahed,Christine Hunter,Daniel O. Claassen,O Román,Victor Sung,Jenna Smith,Sarah Janicki,Ronda Clouse,Marie Saint‐Hilaire,Anna DePold Hohler,Denyse Turpin,Raymond James,Ramón Rodríguez,Kyle Rizer,Karen E. Anderson,Hope Heller,Alexis Carlson,Susan R. Criswell,Brad A. Racett,Fredy J. Revilla,Frederick Nucifora,Russell L. Margolis,Mary Jane Ong,Tilak Mendis,N. M. P. Mendis,Carlos Singer,Mónica Quesada,Jane S. Paulsen,Thomas Brashers-Krug,Amanda C. Miller,Jane Kerr,Richard Dubinsky,Carolyn Steele Gray,Stewart A. Factor,Elaine Sperin,Eric Molho,Mary Eglow,Sharon Evans,Rajeev Kumar,Christina Reeves,Ali Samii,Sylvain Chouinard,Monica Beland,Burton L. Scott,Patrick Hickey,Sherali Esmail,Wai Lun Alan Fung,Clare Gibbons,Lina Qi,Amy Colcher,Cory Hackmyer,Andrew McGarry,Kevin J. Klos,Mark Gudesblatt,Lori Fafard,Laura Graffitti,Daniel Schneider,Rohit Dhall,Joanne Wojcieszek,Kathrin La Faver,Andrew P. Duker,Erin Neefus,Hilary E. Wilson–Pérez,David Shprecher,Paola Wall,Karen Blindauer,Lynn Wheeler,James T. Boyd,Emily Houston,Eric S. Farbman,Pinky Agarwal,Shirley Eberly,Arthur Watts,Pierre N. Tariot,Andrew Feigin,Scott Evans,Chris Beck,Constance Orme,Jon Edicola,Emily Christopher
出处
期刊:JAMA [American Medical Association]
卷期号:316 (1): 40-40 被引量:332
标识
DOI:10.1001/jama.2016.8655
摘要

Importance

Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity.

Objective

To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease.

Design, Setting, and Participants

Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites.

Interventions

Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout.

Main Outcomes and Measures

Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form– physical functioning subscale score (SF-36), and the change in the Berg Balance Test.

Results

Ninety patients with Huntington disease (mean age, 53.7 years; 40 women [44.4%]) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was –2.5 units (95% CI, –3.7 to –1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, –0.3 to 2.3;P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia.

Conclusions and Relevance

Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.

Trial Registration

clinicaltrials.gov Identifier:NCT01795859
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粗心的蜡烛完成签到,获得积分10
1秒前
无尘发布了新的文献求助10
2秒前
科研通AI2S应助集力申采纳,获得10
2秒前
略略略发布了新的文献求助10
3秒前
4秒前
奔奔发布了新的文献求助10
4秒前
丘比特应助喜悦的琳采纳,获得10
5秒前
白小黑发布了新的文献求助10
6秒前
我是老大应助迷途采纳,获得10
7秒前
and999发布了新的文献求助10
7秒前
li发布了新的文献求助10
8秒前
北极熊完成签到,获得积分10
8秒前
浅尝离白应助白苏采纳,获得30
8秒前
yu发布了新的文献求助10
9秒前
我是老大应助山上的树采纳,获得10
11秒前
研友_8Kedgn发布了新的文献求助10
12秒前
zhouleiwang应助董竹君采纳,获得10
12秒前
13秒前
15秒前
Hello应助章鱼采纳,获得10
15秒前
16秒前
喜悦的琳发布了新的文献求助10
17秒前
星辰大海应助Tasker-X采纳,获得10
18秒前
科研通AI2S应助6666采纳,获得10
19秒前
19秒前
21秒前
小蘑菇应助djbj2022采纳,获得10
22秒前
23秒前
Aria_chao发布了新的文献求助10
24秒前
25秒前
26秒前
26秒前
26秒前
上官若男应助Dr.Liujun采纳,获得10
28秒前
30秒前
董竹君发布了新的文献求助10
30秒前
林齐发布了新的文献求助10
31秒前
丘比特应助端庄之云采纳,获得10
32秒前
33秒前
33秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146409
求助须知:如何正确求助?哪些是违规求助? 2797811
关于积分的说明 7825638
捐赠科研通 2454147
什么是DOI,文献DOI怎么找? 1306157
科研通“疑难数据库(出版商)”最低求助积分说明 627642
版权声明 601503